ClinicalTrials.gg

Program

NTQ6179

A development code.

In Sino Biopharmaceutical's pipeline, SSTR2. Its studies are mostly in Acromegaly, led by Sino Biopharmaceutical.

Furthest: phase 1, since Oct 20, 20261 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Oct 20, 2026Oct 20, 2026Apr 2027phase 1 · NCT07909837
  • Named in Sino Biopharmaceutical’s own pipeline as NTQ6179, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2026First study: phase 1 study in AcromegalyFirst studyNCT07909837 · 56 planned · China

Ahead

  1. Apr 2027Primary completion: phase 1 study in AcromegalyNCT07909837

TargetBeta

“SSTR2”the company's pipeline, read by Claude · source

Other programs on SSTR2

ProgramCompanyFurthest phaseStudies
OctreotideruleNovartisphase 436
PaltusotineruleVertex Pharmaceuticalsphase 39
actinium AC-225 dotatateBristol-Myers Squibbphase 33
SSTR2-targeting Non-peptide Drug Conjugate CRN09682ruleVertex Pharmaceuticalsphase 21
Actinium Ac 225 SSTR2-targeted Agent RYZ401Bristol-Myers Squibbphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07909837Acromegaly · China1RecruitingApr 202756

How it is read

Names in the registry

  • “NTQ6179”, 1 entry

Codes read as this program: NTQ6179.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.